CTP 354

Drug Profile

CTP 354

Alternative Names: C-21191; CTP-354; D-L838417

Latest Information Update: 02 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Analgesics; Antispastics; Fluorobenzenes; Organic deuterium compounds; Pyridazines; Small molecules; Triazoles
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Muscle spasticity; Neuropathic pain

Most Recent Events

  • 01 Jan 2015 Suspended - Phase-I for Muscle spasticity and Neuropathic pain (In volunteers) in USA (PO)
  • 13 Oct 2014 Adverse events & pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 139th Annual Meeting of the American Neurological Association (ANA-2014)
  • 01 Oct 2014 Concert Pharmaceuticals completes a phase I trial in Healthy volunteers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top